{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:07:05Z","timestamp":1794809225207,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901850"],"award-info":[{"award-number":["81901850"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072022"],"award-info":[{"award-number":["82072022"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771956"],"award-info":[{"award-number":["81771956"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The response to programmed death-1 (PD-1) blockade varies in hepatocellular carcinoma (HCC). We utilize a panel of 16 serum factors to show that a circulating level of serum amyloid A (SAA)\u2009&gt;\u200920.0\u2009mg\/L has the highest accuracy in predicting anti-PD-1 resistance in HCC. Further experiments show a correlation between peritumoral SAA expression and circulating SAA levels in patients with progressive disease after PD-1 inhibition. In vitro experiments demonstrate that SAA induces neutrophils to express PD-L1 through glycolytic activation via an LDHA\/STAT3 pathway and to release oncostatin M, thereby attenuating cytotoxic T cell function. In vivo, genetic or pharmacological inhibition of STAT3 or SAA eliminates neutrophil-mediated immunosuppression and enhances antitumor efficacy of anti-PD-1 treatment. This study indicates that SAA may be a critical inflammatory cytokine implicated in anti-PD-1 resistance in HCC. Targeting SAA-induced PD-L1<jats:sup>+<\/jats:sup> neutrophils through STAT3 or SAA inhibition may present a potential approach for overcoming anti-PD1 resistance.<\/jats:p>","DOI":"10.1038\/s41467-024-46118-w","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T16:03:06Z","timestamp":1708963386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2236-6252","authenticated-orcid":false,"given":"Meng","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-3953","authenticated-orcid":false,"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9095-4128","authenticated-orcid":false,"given":"Shuang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-7472","authenticated-orcid":false,"given":"Xiaojun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-8895","authenticated-orcid":false,"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8254-1040","authenticated-orcid":false,"given":"Ning","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"46118_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249, https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"46118_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 76, 681\u2013693, https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018 (2022).","journal-title":"J. Hepatol."},{"key":"46118_CR3","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.20.02672","volume":"38","author":"JD Gordan","year":"2020","unstructured":"Gordan, J. D. et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J. Clin. Oncol. 38, 4317\u20134345, https:\/\/doi.org\/10.1200\/JCO.20.02672 (2020).","journal-title":"J. Clin. Oncol."},{"key":"46118_CR4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905, https:\/\/doi.org\/10.1056\/NEJMoa1915745 (2020).","journal-title":"N. Engl. J. Med."},{"key":"46118_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","volume":"40","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J. Clin. Oncol. 40, 379\u2013379, https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.379 (2022).","journal-title":"J. Clin. Oncol."},{"key":"46118_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","volume":"40","author":"S Qin","year":"2022","unstructured":"Qin, S. et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. J. Clin. Oncol. 40, 383\u2013383, https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.383 (2022).","journal-title":"J. Clin. Oncol."},{"key":"46118_CR7","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau, T. et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol. 6, e204564, https:\/\/doi.org\/10.1001\/jamaoncol.2020.4564 (2020).","journal-title":"JAMA Oncol."},{"key":"46118_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson, A. B. et al. Hepatobiliary cancers, Version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc Netw. 19, 541\u2013565, https:\/\/doi.org\/10.6004\/jnccn.2021.0022 (2021).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"46118_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro, B., Sarobe, P., Hervas-Stubbs, S. & Melero, I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 525\u2013543, https:\/\/doi.org\/10.1038\/s41575-021-00438-0 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"46118_CR10","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","volume":"73","author":"B Sangro","year":"2020","unstructured":"Sangro, B. et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J. Hepatol. 73, 1460\u20131469, https:\/\/doi.org\/10.1016\/j.jhep.2020.07.026 (2020).","journal-title":"J. Hepatol."},{"key":"46118_CR11","doi-asserted-by":"publisher","first-page":"e004024","DOI":"10.1136\/jitc-2021-004024","volume":"10","author":"N Klumper","year":"2022","unstructured":"Klumper, N. et al. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. J. Immunother. Cancer 10, e004024, https:\/\/doi.org\/10.1136\/jitc-2021-004024 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"46118_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","volume":"76","author":"B Scheiner","year":"2022","unstructured":"Scheiner, B. et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J. Hepatol. 76, 353\u2013363, https:\/\/doi.org\/10.1016\/j.jhep.2021.09.035 (2022).","journal-title":"J. Hepatol."},{"key":"46118_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/00062752-200001000-00012","volume":"7","author":"S Urieli-Shoval","year":"2000","unstructured":"Urieli-Shoval, S., Linke, R. P. & Matzner, Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 7, 64\u201369, https:\/\/doi.org\/10.1097\/00062752-200001000-00012 (2000).","journal-title":"Curr. Opin. Hematol."},{"key":"46118_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.gene.2016.02.044","volume":"583","author":"L Sun","year":"2016","unstructured":"Sun, L. & Ye, R. D. Serum amyloid A1: Structure, function and gene polymorphism. Gene 583, 48\u201357, https:\/\/doi.org\/10.1016\/j.gene.2016.02.044 (2016).","journal-title":"Gene"},{"key":"46118_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","volume":"567","author":"JW Lee","year":"2019","unstructured":"Lee, J. W. et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567, 249\u2013252, https:\/\/doi.org\/10.1038\/s41586-019-1004-y (2019).","journal-title":"Nature"},{"key":"46118_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/ni.1942","volume":"11","author":"C De Santo","year":"2010","unstructured":"De Santo, C. et al. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat. Immunol. 11, 1039\u20131046, https:\/\/doi.org\/10.1038\/ni.1942 (2010).","journal-title":"Nat. Immunol."},{"key":"46118_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2021.05.030","volume":"158","author":"LN He","year":"2021","unstructured":"He, L. N. et al. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1\/PD-L1 monotherapy. Lung Cancer 158, 1\u20138, https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.030 (2021).","journal-title":"Lung Cancer"},{"key":"46118_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon, S. et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat. Rev. Cancer 20, 485\u2013503, https:\/\/doi.org\/10.1038\/s41568-020-0281-y (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"46118_CR19","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1136\/gutjnl-2016-313075","volume":"66","author":"TT Wang","year":"2017","unstructured":"Wang, T. T. et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut 66, 1900\u20131911, https:\/\/doi.org\/10.1136\/gutjnl-2016-313075 (2017).","journal-title":"Gut"},{"key":"46118_CR20","doi-asserted-by":"publisher","first-page":"e002305","DOI":"10.1136\/jitc-2020-002305","volume":"9","author":"H Deng","year":"2021","unstructured":"Deng, H. et al. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. J. Immunother. Cancer 9, e002305, https:\/\/doi.org\/10.1136\/jitc-2020-002305 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"46118_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41575-021-00568-5","volume":"19","author":"D Geh","year":"2022","unstructured":"Geh, D. et al. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 19, 257\u2013273, https:\/\/doi.org\/10.1038\/s41575-021-00568-5 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"46118_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151\u2013172, https:\/\/doi.org\/10.1038\/s41571-021-00573-2 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"46118_CR23","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.trecan.2021.04.007","volume":"7","author":"T Rogers","year":"2021","unstructured":"Rogers, T. & DeBerardinis, R. J. Metabolic plasticity of neutrophils: Relevance to pathogen responses and cancer. Trends Cancer 7, 700\u2013713, https:\/\/doi.org\/10.1016\/j.trecan.2021.04.007 (2021).","journal-title":"Trends Cancer"},{"key":"46118_CR24","doi-asserted-by":"publisher","unstructured":"Wang, L. et al. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut, https:\/\/doi.org\/10.1136\/gutjnl-2021-326070 (2022).","DOI":"10.1136\/gutjnl-2021-326070"},{"key":"46118_CR25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","volume":"145","author":"W Luo","year":"2011","unstructured":"Luo, W. et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732\u2013744, https:\/\/doi.org\/10.1016\/j.cell.2011.03.054 (2011).","journal-title":"Cell"},{"key":"46118_CR26","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/blood.2021012322","volume":"139","author":"N Dhanesha","year":"2022","unstructured":"Dhanesha, N. et al. PKM2 promotes neutrophil activation and cerebral thromboinflammation: therapeutic implications for ischemic stroke. Blood 139, 1234\u20131245, https:\/\/doi.org\/10.1182\/blood.2021012322 (2022).","journal-title":"Blood"},{"key":"46118_CR27","doi-asserted-by":"publisher","first-page":"e20190613","DOI":"10.1084\/jem.20190613","volume":"217","author":"LEA Damasceno","year":"2020","unstructured":"Damasceno, L. E. A. et al. PKM2 promotes Th17 cell differentiation and autoimmune inflammation by fine-tuning STAT3 activation. J. Exp. Med. 217, e20190613, https:\/\/doi.org\/10.1084\/jem.20190613 (2020).","journal-title":"J. Exp. Med."},{"key":"46118_CR28","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593, https:\/\/doi.org\/10.1126\/science.aar3593 (2018).","journal-title":"Science"},{"key":"46118_CR29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365, https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9 (2020).","journal-title":"Lancet Oncol."},{"key":"46118_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336, https:\/\/doi.org\/10.1038\/s41590-019-0312-6 (2019).","journal-title":"Nat. Immunol."},{"key":"46118_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000516899","volume":"10","author":"M Morita","year":"2021","unstructured":"Morita, M. et al. Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody. Liver Cancer 10, 380\u2013393, https:\/\/doi.org\/10.1159\/000516899 (2021).","journal-title":"Liver Cancer"},{"key":"46118_CR32","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502, https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2 (2017).","journal-title":"Lancet"},{"key":"46118_CR33","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/hep.29904","volume":"68","author":"Y Kurebayashi","year":"2018","unstructured":"Kurebayashi, Y. et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology 68, 1025\u20131041, https:\/\/doi.org\/10.1002\/hep.29904 (2018).","journal-title":"Hepatology"},{"key":"46118_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhep.2022.04.020","volume":"77","author":"M Barcena-Varela","year":"2022","unstructured":"Barcena-Varela, M. Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies. J. Hepatol. 77, 9\u201311, https:\/\/doi.org\/10.1016\/j.jhep.2022.04.020 (2022).","journal-title":"J. Hepatol."},{"key":"46118_CR35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"AL Cheng","year":"2020","unstructured":"Cheng, A. L., Hsu, C., Chan, S. L., Choo, S. P. & Kudo, M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J. Hepatol. 72, 307\u2013319, https:\/\/doi.org\/10.1016\/j.jhep.2019.09.025 (2020).","journal-title":"J. Hepatol."},{"key":"46118_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","volume":"3","author":"DL Rimm","year":"2017","unstructured":"Rimm, D. L. et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 3, 1051\u20131058, https:\/\/doi.org\/10.1001\/jamaoncol.2017.0013 (2017).","journal-title":"JAMA Oncol."},{"key":"46118_CR37","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","volume":"5","author":"S Lu","year":"2019","unstructured":"Lu, S. et al. Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: A systematic review and meta-analysis. JAMA Oncol. 5, 1195\u20131204, https:\/\/doi.org\/10.1001\/jamaoncol.2019.1549 (2019).","journal-title":"JAMA Oncol."},{"key":"46118_CR38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu, A. X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282\u2013296, https:\/\/doi.org\/10.1016\/S1470-2045(18)30937-9 (2019).","journal-title":"Lancet Oncol."},{"key":"46118_CR39","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599\u20131611, https:\/\/doi.org\/10.1038\/s41591-022-01868-2 (2022).","journal-title":"Nat. Med."},{"key":"46118_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc.2017.5","volume":"17","author":"G Schneider","year":"2017","unstructured":"Schneider, G., Schmidt-Supprian, M., Rad, R. & Saur, D. Tissue-specific tumorigenesis: context matters. Nat. Rev. Cancer 17, 239\u2013253, https:\/\/doi.org\/10.1038\/nrc.2017.5 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"46118_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152\u2013164, https:\/\/doi.org\/10.1038\/s41591-020-1131-x (2021).","journal-title":"Nat. Med."},{"key":"46118_CR42","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","volume":"175","author":"M Grohmann","year":"2018","unstructured":"Grohmann, M. et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell 175, 1289\u20131306 e1220, https:\/\/doi.org\/10.1016\/j.cell.2018.09.053 (2018).","journal-title":"Cell"},{"key":"46118_CR43","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41422-023-00831-1","volume":"33","author":"L Wu","year":"2023","unstructured":"Wu, L. et al. An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte\u2013tumor cell crosstalk, local immunosuppression and tumor progression. Cell Res. 33, 585\u2013603, https:\/\/doi.org\/10.1038\/s41422-023-00831-1 (2023).","journal-title":"Cell Res."},{"key":"46118_CR44","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1136\/gutjnl-2021-326350","volume":"71","author":"LG Lu","year":"2022","unstructured":"Lu, L. G. et al. PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma. Gut 71, 2551\u20132560, https:\/\/doi.org\/10.1136\/gutjnl-2021-326350 (2022).","journal-title":"Gut"},{"key":"46118_CR45","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1002\/1878-0261.13263","volume":"16","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis. Mol. Oncol. 16, 2861\u20132880, https:\/\/doi.org\/10.1002\/1878-0261.13263 (2022).","journal-title":"Mol. Oncol."},{"key":"46118_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cmet.2019.10.013","volume":"31","author":"C Zhang","year":"2020","unstructured":"Zhang, C. et al. STAT3 activation-induced fatty acid oxidation in CD8(+) T effector cells is critical for obesity-promoted breast tumor growth. Cell Metab. 31, 148\u2013161 e145, https:\/\/doi.org\/10.1016\/j.cmet.2019.10.013 (2020).","journal-title":"Cell Metab."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46118-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46118-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46118-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T16:05:46Z","timestamp":1708963546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46118-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["46118"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-46118-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"20 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1754"}}